A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

NCT04516447 · readout in 681 d

Sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc (industry) · ZNTL — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

172estimated

Sites

Countries

Australia, Bosnia and Herzegovina, Bulgaria +4

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2020-10-26

actual

When the study began enrolling

Primary completion

2028-06-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-06-30

estimated

The whole study's end, after follow-up

First posted

2020-08-18

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-04-07

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Solid Tumor
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions

Drug: Azenosertib — also filed as ZN-c3
Drug: Carboplatin
Drug: Pegylated liposomal doxorubicin
Drug: Paclitaxel
Drug: Gemcitabine
Biological: Bevacizumab

Primary outcomes

what the primary-completion date above is the date OF

Part 1: To investigate the safety and tolerability of azenosertib in combination with PLD, carboplatin, paclitaxel, or gemcitabine

measured Through study completion, an average of 1 year

Part 1: To identify the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of azenosertib in combination with PLD, carboplatin, paclitaxel, or gemcitabine

measured Through Cycle 1 (cycle is 28 days for PLD or paclitaxel, and 21 days for carboplatin, or gemcitabine)

Part 2: To estimate the safety/tolerability of azenosertib in combination with bevacizumab

measured Through study completion, an average of 1 year

Part 2: To identify the recommended dose for Part 2 Dose Expansion

measured Through Cycle 1 (21 days)

Permalink · ZNTL's whole pipeline · Catalyst calendar · Every registered study · What changed